Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting

Biochemical Pharmacology

Volumn 65, Issue 11, 2003, Pages 1807-1815

  Delahoussaye, Yvette M ^a   Hay, Michael P ^b   Pruijn, Frederik B ^b   Denny, William A ^b   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreductive drugs; DNA targeting; Hypoxia; SN26955; Tirapazamine; Tumor

Indexed keywords

ACRIDINE; CYTOTOXIN; DOUBLE STRANDED DNA; OXIDOREDUCTASE; SN 26955; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; CELL KILLING; CELL METABOLISM; CHROMATOPHORE; CYTOPLASM; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; GENE TARGETING; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; REDUCTION;

EID: 0038054178     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00199-0     Document Type: Article

References (30)

1. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer. 67:1993;1163-1170.
2. Denny W.A., Wilson W.R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert. Opin. Investig. Drugs. 9:2000;2889-2901.
3. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-40.
4. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;285-289.
5. Sartorelli A.C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 48:1988;775-778.
6. Brown J.M., The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture Cancer Res. 59:1999;5863-5870.
7. Craighead P.S., Pearcey R., Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;791-795.
8. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., Talbot D., Rey A., Butler T.W., Hirsh V., Olver I., Bergman B., Ayoub J., Richardson G., Dunlop D., Arcenas A., Vescio R., Viallet J., Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J. Clin. Oncol. 18:2000;1351-1359.
9. Rischin D., Peters L., Hicks R., Hughes P., Fisher R., Hart R., Sexton M., D'Costa I., von Roemeling R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19:2001;535-542.
10. Wang J., Biedermann K.A., Brown J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477.
11. Daniels J.S., Gates K.S., Tronche C., Greenberg M.M. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 11:1998;1254-1257.
12. Baker M.A., Zeman E.M., Hirst V.K., Brown J.M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48:1988;5947-5952.
13. Wang J., Biedermann K.A., Wolf C.R., Brown J.M. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br. J. Cancer. 67:1993;321-325.
14. Patterson A.V., Saunders M.P., Chinje E.C., Patterson L.H., Stratford I.J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des. 13:1998;541-573.
15. Evans J.E., Yudoh K., Delahoussaye Y.M., Brown J.M. Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res. 58:1998;2098-2101.
16. Berezney R., Wei X. The new paradigm: integrating genomic function and nuclear architecture. J. Cell Biochem. 30-31(Suppl):1998;238-242.
17. Delahoussaye Y.M., Evans J.E., Brown J.M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol. 62:2001;1201-1209.
18. Peters K.B., Wang H., Brown J.M., Iliakis G., Inhibition of DNA replication by tirapazamine Cancer Res. 61:2001;5425-5431.
19. Peters K.B., Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 62:2002;5248-5253.
20. Fortune J.M., Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64:2000;221-253.
21. Wouters B.G., Delahoussaye Y.M., Evans J.W., Birrell G.W., Dorie M.J., Wang J., MacDermed D., Chiu R.K., Brown J.M. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 61:2001;145-152.
22. Hicks K.O., Fleming Y., Siim B.G., Koch C.J., Wilson W.R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;641-649.
23. Kyle A.H., Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 43:1999;213-220.
24. Robbins RF, Schofield K. Polyazabicyclic compounds. Part II. Further derivatives of benzo-1,2,4-triazine. J Chem Soc 1957:3186-94.
25. Henderson L.M., Chappell J.B. Dihydrorhodamine 123: a fluorescent probe for superoxide generation? Eur. J. Biochem. 217:1993;973-980.
26. Bump E.A., Cerce B.A., Al-Sarraf R., Pierce S.M., Koch C.J. Radioprotection of DNA in isolated nuclei by naturally occurring thiols at intermediate oxygen tension. Radiat. Res. 132:1992;94-104.
27. Olive P.L. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br. J. Cancer. 71:1995;529-536.
28. McGhee J.D., von Hippel P.H. Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J. Mol. Biol. 86:1974;469-489.
29. Lloyd R.V., Duling D.R., Rumyantseva G.V., Mason R.P., Bridson P.K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol. Pharmacol. 40:1991;440-445.
30. Rauth A.M., Melo T., Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;755-762.